![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 29, 2020
May 29, 2020
A Standing Main Member of ECOG-ACRIN since 1986
May 29, 2020
April 15, 2020
Seamless patient mangement during the pandemic; COVID-19 Virtual Town Hall for Community Physicians and Research Staff; remembering Dr. Uma Rao; recognizing the John H. Stroger, Jr. Hospital of Cook County Minority Underserved NCORP; spotlight on the EROS trial, which is evaluating a program to help women with cancer and their physicians plan for reproductive health and preservation of sexuality during and after cancer treatment
April 15, 2020
For patients who have a pathologic complete response (pCR) after 12 weeks of pre-operative THP (single agent taxane plus trastuzumab and pertuzumab), is it safe to omit additional therapy after surgery?
April 15, 2020
A single-arm phase II trial evaluating the effectiveness of treatment before surgery with encorafenib and binimetinib
April 15, 2020
April 15, 2020
A Standing Main Member of ECOG-ACRIN since 2002
February 28, 2020
January meeting with NCI leaders and the Cooperative Group Chairs; Congress increases NCI and overall NIH budget for FY 2020; EA opens two new trials, one for pancreatic cyst monitoring (EA2185) and the other to evaluate nivolumab in head and neck cancer (EA3161); plans are underway for the next Comis Symposium
February 28, 2020
Mike Thompson writes that educating and engaging the public--both via social media and in person--is necessary to sustain a national clinical trials infrastructure and continue advancing cancer research
February 28, 2020
February 28, 2020
This trial is evaluating maintenance nivolumab versus observation following intensity-modulated radiation therapy and cisplatin